XOMA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.10M

+27.38%

-0.126

+110%

11.80M

-25.84%

-0.055

-191.67%

11.70M

-10.88%

0.075

-82.95%

Estimates Revision

The market is revising Upward the revenue expectations for XOMA Royalty Corporation (XOMA) for FY2025, with the revenue forecasts being adjusted by 1.48% over the past three months. During the same period, the stock price has changed by -17.69%.

Revenue Estimates for FY2025

Revise Upward

+1.48%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+54.97%

In Past 3 Month

Stock Price

Go Down

-17.69%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

50.00

Averages

69.67

High

104.00

Current: 0.000

Low

50.00

Averages

69.67

High

104.00

Lucid Capital

NULL -> Buy

initiated

$76

2025-12-09

Reason

Lucid Capital

Price Target

$76

2025-12-09

initiated

NULL -> Buy

Reason

Lucid Capital initiated coverage of Xoma with a Buy rating and $76 price target. The company has assembled a royalty portfolio from six commercial and nine Phase 3- stage small molecule and biological assets, the analyst tells investors in a research note. The firm says Xoma expects to collect over $1B in milestones and royalties over the next 15 years. Lucid believes that by building a diversified portfolio, the company mitigates single-asset risk while retaining exposure to substantial long-term value creation.

Benchmark

Robert Wasserman

Strong Buy

Initiates

$35

2025-04-17

Reason

Benchmark

Robert Wasserman

Price Target

$35

2025-04-17

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Xoma with a Buy rating and $35 price target. Xoma has expanded its royalty aggregate business through acquisitions and internal growth over the past several years, notes the analyst, who expects the R&D pipeline and recently completed commercial asset acquisitions to continue to drive double digit revenue growth over the next several years.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$104

2025-03-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$104

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$104

2025-03-19

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$104

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$123 → $104

2025-02-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$123 → $104

2025-02-03

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Xoma Royalty Corp (XOMA.O) is 96.85, compared to its 5-year average forward P/E of -15.15. For a more detailed relative valuation and DCF analysis to assess Xoma Royalty Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.15

Current PE

96.85

Overvalued PE

44.27

Undervalued PE

-74.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.49

Current EV/EBITDA

34.58

Overvalued EV/EBITDA

105.44

Undervalued EV/EBITDA

-60.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

18.34

Current PS

5.82

Overvalued PS

34.05

Undervalued PS

2.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XOMA News & Events

Events Timeline

No data

News

7.0

15:51 PMPRnewswire

XOMA Shares Plunge 22.76% Following Phase 3 Study Failure

7.0

2025-12-30Globenewswire

XOMA Shares Plunge 22.76% Following Phase 3 Study Failure

9.0

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

People Also Watch

Frequently Asked Questions

What is Xoma Royalty Corp (XOMA) stock price today?

The current price of XOMA is 29.92 USD — it has increased 9.96 % in the last trading day.

What is Xoma Royalty Corp (XOMA)'s business?

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

What is the price predicton of XOMA Stock?

What is Xoma Royalty Corp (XOMA)'s revenue for the last quarter?

Xoma Royalty Corp revenue for the last quarter amounts to 9.35M USD, increased 29.93 % YoY.

What is Xoma Royalty Corp (XOMA)'s earnings per share (EPS) for the last quarter?

Xoma Royalty Corp. EPS for the last quarter amounts to 0.70 USD, decreased -144.03 % YoY.

What changes have occurred in the market's expectations for Xoma Royalty Corp (XOMA)'s fundamentals?

How many employees does Xoma Royalty Corp (XOMA). have?

Xoma Royalty Corp (XOMA) has 13 emplpoyees as of January 08 2026.

What is Xoma Royalty Corp (XOMA) market cap?

Today XOMA has the market capitalization of 371.49M USD.